Verona Pharma (VRNA) to Release Earnings on Monday

Verona Pharma (NASDAQ:VRNA) is scheduled to release its earnings data before the market opens on Monday, November 4th. Analysts expect Verona Pharma to post earnings of ($0.44) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same period in the prior year, the company posted ($0.11) EPS. On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Verona Pharma Trading Down 1.7 %

NASDAQ:VRNA opened at $33.86 on Monday. The firm has a market capitalization of $2.75 billion, a P/E ratio of -21.99 and a beta of 0.44. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma has a one year low of $11.39 and a one year high of $35.62. The company’s 50-day simple moving average is $29.96 and its 200 day simple moving average is $21.54.

Insider Activity

In related news, CFO Mark W. Hahn sold 249,728 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $4.38, for a total transaction of $1,093,808.64. Following the completion of the sale, the chief financial officer now directly owns 14,089,960 shares in the company, valued at approximately $61,714,024.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Verona Pharma news, CEO David Zaccardelli sold 245,784 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92. Following the completion of the sale, the chief executive officer now owns 15,004,920 shares in the company, valued at $65,721,549.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Mark W. Hahn sold 249,728 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.38, for a total value of $1,093,808.64. Following the completion of the transaction, the chief financial officer now directly owns 14,089,960 shares in the company, valued at $61,714,024.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 868,840 shares of company stock valued at $3,805,519 in the last quarter. 4.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on VRNA. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Verona Pharma in a report on Tuesday, October 1st. Wells Fargo & Company began coverage on Verona Pharma in a research report on Thursday, October 3rd. They set an “overweight” rating and a $50.00 price objective on the stock. Canaccord Genuity Group boosted their target price on Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Finally, Truist Financial raised their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $39.33.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.